Sof foyda bo'yicha sotuv rentabelligi: Adlai Nortye Ltd. (ANL)

adlainortye.com - ANL emitenti grafik logotipi

Onkologik dori vositalarini ishlab chiqishdagi xalqaro yetakchilik tajribasi Adlai Nortye Ltd. (ANL) biznesining kengayishi uchun asos yaratdi. Sof daromadlilik tendentsiyasi ushbu o'sishni vizuallashtiradi, bunda -124.80 eng so'nggi metrika qiymatini aks ettiradi. Chidamlilikka ega o'smalarga qarshi innovatsion buparlisibning ishlab chiqilishi kompaniyaning salohiyatini oshiradi, Osiyo va AQShdagi markazlar tarmog'ining kengayishi hamda bemorlarning to'liq saqlab qolinishi esa FDA tasdig'i oldidan barqarorlikni ta'minlaydi.

Adlai Nortye (ANL) Sotuvning sof rentabelligi: 21.02.2024 - 20.11.2026 davri uchun

Adlai Nortye Ltd (ANL) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- aksiya kursi va ekspertlarning narx prognozi:
- kompaniyaning birjadagi kapitallashuv ko'rsatkichlari:
Kompaniyaning fundamental baholanishi:Adlai Nortye Ltd, ANL
Adlai Nortye ishlab chiqargan mahsulot

Xitoy va AQSh o'rtasidagi geosiyosiy keskinliklar va sanksiyalar Adlai Nortye Ltd. (ANL) kompaniyasining global klinik sinovlariga to'sqinlik qilmoqda. Ushbu logistik uzilishlar operatsion xarajatlarga bevosita ta'sir ko'rsatib, yakuniy foydani buzmoqda. Ushbu ko'rsatkich jami daromad ichidagi sof foyda ulushini o'lchaydi va biznesning real samaradorligini belgilaydi. Mazkur metrika emitentning moliyaviy barqarorligini baholash imkonini beradi va aktiv uchun haddan tashqari ko'p to'lov qilishning oldini oladi. Sof foyda marjasi tendentsiyasining tahlili kompaniyaning foyda keltirish qobiliyatini tasdiqlaydi.

Raqobatdosh kompaniyalar tahlili

ONC: Sotuvning sof marjinal rentabelligi|Sof marja Halozyme Inc. (HALO)|Sof marja RevMed|Sotuvning sof rentabelligi AAPG (Ascentage Pharma Group)|Sotuvning sof marjinal rentabelligi CGON|UroGen Pharma - Sotuvning sof rentabelligi|Bicara Therapeutics - Sof foyda bo'yicha sotuv rentabelligi|Sotuvning sof marjinal rentabelligi Personalis Inc PSNL|Erasca Oncology - Sotuvning sof marjinal rentabelligi|Sof foyda normasi DCTH (Delcath Corp)|YMAB: Sotuvning sof marjinal rentabelligi|AURA - Kompaniya sotuv marjasi|CADL (Candel Therapeutics Inc.) - Sotuvning sof marjinal rentabelligi|Sotuvning sof rentabelligi ARAY (Accuray)|Sof foyda bo'yicha sotuv rentabelligi SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Sof marja|Sof marja Citius Oncology, Inc. CTOR|HURA - Sof foyda bo'yicha sotuv rentabelligi|protaratx.com - Sotuvning sof marjinal rentabelligi|FATE - Sotuvning sof marjinal rentabelligi|WHWK: Sotuvning sof marjinal rentabelligi|TScan Therapeutics (TCRX) - Sotuvning sof marjinal rentabelligi|Sof marja Champions Oncology|Sof marja XBIT|Sotuvning sof marjinal rentabelligi CVM|Sof foyda bo'yicha sotuv rentabelligi OS Therapies Inc. OSTX|Sof marja Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Sof marja|Veru Inc - Sotuvning sof marjinal rentabelligi|Kompaniya sotuv marjasi Tempest Therapeutics TPST|XLO: Sotuvning sof marjinal rentabelligi|Enochian BioSciences (RENB) - Sotuvning sof marjinal rentabelligi|Sof foyda bo'yicha sotuv rentabelligi MURA|Kairos Pharma Ltd - Sof foyda marjasi|Sotuvning sof marjinal rentabelligi OKUR|CytoMed Therapeutics Limited (GDTC) - Sof foyda bo'yicha marjinallik|Sotuvning sof marjinal rentabelligi CRIS (Curis, Inc.)|APLM: Sotuvning sof rentabelligi|Tharimmune Corporation - Sotuvning sof marjinal rentabelligi|ADVB: Sof marja|GNPX: Sotuvning sof marjinal rentabelligi|CLDI (Calidi Biotherapeutics Inc.) - Sof marja|Sof marja Sunshine Biopharma, Inc.|Sotuvning sof marjinal rentabelligi xeneticbio.com|Sof marja Salarius (SLRX)|Sof foyda bo'yicha sotuv rentabelligi Purple Biotech PPBT|Sof marja American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Sof marja|Checkpoint Therapeutics Inc. - Sotuvning sof marjinal rentabelligi|Sof foyda normasi ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Sof foyda bo'yicha sotuv rentabelligi|Ikena Oncology, Inc. - Sof foyda normasi|Sof foyda bo'yicha sotuv rentabelligi NTBL|VIRX: Sof foyda normasi|Sof marja MorphoSys Corporation (MOR)|NAYA - Sof marja|Sotuvning sof marjinal rentabelligi AAPGV (Ascentage)